The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Mirum Pharmaceuticals Inc shares valued at $623,853 were sold by Quan Joanne on Jan 20 ’26. At $90.27 per share, Quan Joanne sold 6,911 shares. The insider’s holdings dropped to 11,305 shares worth approximately $1.09 million following the completion of this transaction.
Also, Ramasastry Saira sold 2,000 shares, netting a total of over 181,980 in proceeds. Following the sale of shares at $90.99 each, the insider now holds 0 shares.
Before that, SAIRA RAMASASTRY had added 2,000 shares to its account. In a trade valued at $181,980, the Director bought Mirum Pharmaceuticals Inc shares for $90.99 each.
As published in their initiating research note from TD Cowen on September 24, 2025, Mirum Pharmaceuticals Inc [MIRM] has been a Buy and the price target has been revised to $95. Earlier on April 17, 2024, Stifel initiated its rating. Their recommendation was “a Buy” for MIRM stock.
Analyzing MIRM Stock Performance
On last trading session, Mirum Pharmaceuticals Inc [NASDAQ: MIRM] rose 2.96% to $96.03. The stock’s lowest price that day was $91.5197, but it reached a high of $96.13 in the same session. During the last five days, there has been a surge of approximately 5.93%. Over the course of the year, Mirum Pharmaceuticals Inc shares have jumped approximately 100.15%.
Is Mirum Pharmaceuticals Inc subject to short interest?
Stocks of Mirum Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.9 million shares to 8.36 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 7.46 million shares. A jump of 10.74% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.24 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.24.
Which companies own the most shares of Mirum Pharmaceuticals Inc (MIRM)?
In terms of Mirum Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 100.5 in the next 12 months, up nearly 7.75% from the previous closing price of $93.27. Analysts anticipate Mirum Pharmaceuticals Inc stock to reach 140 by 2026, with the lowest price target being 89. In spite of this, 9 analysts ranked Mirum Pharmaceuticals Inc stock as Buy at the end of 2026. On December 18, 2023, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $58.
